Floatz logo

Maridebart Cafraglutide

Diastolic Heart Failure

Amgenantibody_drug_conjugatePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

17 Active assets in the Diastolic Heart Failure cohort.

Asset / SponsorPhaseRating
Semaglutide
Mayo Clinic
Phase 4BBB
Metformin
Sara ElAdawy
Phase 4BBB
Tirzepatide
Yunlong Wang
Phase 4BBB
Liraglutide
Leiden University Medical Center
Phase 4BBB
Benzbromarone
National Defense Medical Center, Taiwan
Phase 4BB

View all 23 →

Same molecule, other indications

Maridebart Cafraglutide is also rated in:

atherosclerotic cardiovascular diseaseActive
B
Indicative · Phase 3
60 / 100
View asset →
heart failureActive
B
Indicative · Phase 3
60 / 100
View asset →
obesity disorderActive
B
Indicative · Phase 3
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →